Meeting
2023 ASCO Annual Meeting
Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies.
Authors
Ross Firestone
Memorial Sloan Kettering Cancer Center, New York, NY
Ross Firestone , Tala Shekarkhand , Dhwani Patel , Carlyn Rose Co Tan , Malin Hultcrantz , Alexander M. Lesokhin , Sham Mailankody , Hani Hassoun , Urvi A Shah , Neha Korde , Kylee Maclachlan , Heather Jolie Landau , Michael Scordo , David J. Chung , Gunjan L. Shah , Oscar Boutros Lahoud , Sergio Giralt , Saad Zafar Usmani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8049)
DOI
10.1200/JCO.2023.41.16_suppl.8049
Abstract #
8049
Poster Bd #
41
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM).
First Author: Julia Piasecki
Poster
2019 ASCO Annual Meeting
The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain.
First Author: Lu Han
Poster
2017 ASCO Annual Meeting
First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.
First Author: Jesus G. Berdeja
Poster
2022 ASCO Annual Meeting
Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated results from MonumenTAL-1.
First Author: Monique C. Minnema